At present, no treatments exist that effectively target and eliminate papillomaviruses (PVs) from infected cells or prevent its replication. We are employing a strategy to prevent virus replication in PV-infected cells through the conditional expression of the herpes simplex virus type 1 thymidine kinase (TK) gene. Expression of TK in this system is expected to be triggered by a homologous recombination event between the endogenous PV genome and a nonexpressing TK gene cassette. Recombination between these two DNAs is expected to change the nonexpressing cassette into a form that expresses TK. Various constructs were generated to express the TK in the above manner.
Introduction
Papillomaviruses (PVs) are small, nonenveloped, double-stranded DNA tumor viruses. [1] [2] [3] [4] During productive infection, the virus gains access to the basal epithelium where the viral DNA replicates to a low level of approximately 50 copies per infected cell. [1] [2] [3] [4] Virion production requires terminal differentiation of the host cell during which the virus replicates to high levels, produces the capsid proteins L1 and L2, and mature virions are formed. [1] [2] [3] [4] The shed virions then reinfect the basal epithelium or they can infect new hosts. PVs infect many different species of animals in nature, and to date more than 100 types of human papillomaviruses (HPVs) have been identified. [1] [2] [3] [4] Certain mucosatropic HPVs such as types 6 and 11 cause low-grade cervical lesions, while others such as HPV-16, HPV-18, HPV-31, and HPV-45 are strongly associated with cervical cancer and to a lesser degree with other anogenital cancers. [1] [2] [3] [4] The HPV genome often integrates into the host chromosome at the viral E2 locus in these malignancies, and the resulting cells do not express the viral regulatory protein E2. [1] [2] [3] [4] The loss of E2 activity results in the overexpression of the viral E6 and E7 oncoproteins, which inactivate the functions of the cellular tumor suppressor proteins p53 and RB, respectively. [1] [2] [3] [4] The E6 and E7 proteins also target several other cellular pathways that contributes to their oncogenic potential. [1] [2] [3] [4] Malignancies associated with HPV infection usually occur several years after the primary infection and the oncogenic potential of HPVs is greatly increased by its ability to cause persistent infections. Although low-risk HPVs such as types 6 and 11 are rarely associated with cancer, they often cause painful long-term infections. [1] [2] [3] [4] Also, cutaneous HPVs such as types 1 and 2 can cause benign lesions that can be painful or cosmetically unacceptable and require medical treatment. [1] [2] [3] [4] Untreated, the above types of lesions may persist for decades without clearance or regression, and surgical treatment does not prevent recurrence. [1] [2] [3] [4] At present, no effective treatment is available to target and eliminate HPV from persistently infected cells. During the persistent state, large population of host cells harbor episomal HPV DNA. This allows a potential opportunity to disrupt the episomal HPV genome by an approach involving homologous recombination. In contrast to the chromosome, homologous recombination between episomal DNA elements occurs more frequently. Intermolecular homologous recombination between related plasmids cotransfected into immortalized cells occurs in roughly 0.2-1% of recovered plasmids. 5, 6 These frequencies have been shown to be even higher in a bovine papillomavirus (BPV)-based mammalian plasmids over extended time periods. 7 In this study, we have developed a DNA recombination-based approach for the conditional expression of the suicide HSV-1 thymidine kinase (TK) gene. The gene cassette is designed to express TK, through homologous recombination, only in cells that contain BPV DNA. Transfection of the DNA cassette resulted in the expression of TK in cell lines containing the BPV DNA, whereas little or no expression was observed in cells lacking the BPV sequences. We also utilized an adenoassociated virus (AAV)-TK cassette for the specific expression of the HSV-1 TK gene in BPV-1-containing cells. In combination with ganciclovir (GCV) therapy, this novel approach in gene therapy may allow elimination of PV infections by targeting the viral DNA specifically in infected cells.
Results

Development of recombination-dependent TK expression cassettes
We developed a strategy for the expression of the HSV-1 TK gene conditional upon its recombination with PV sequences. The desirable features of this gene cassette are that it must not express TK, but in the presence of PV sequences in the cell, it should undergo homologous recombination, leading to the expression of the TK gene. The DNA sequence encoding the amino-terminal region of TK has been shown to act as a weak promoter in some tissues. 8 As TK expression must be tightly regulated in this system, we utilized an amino-terminal-deleted version of TK in which this promoter is deleted. This TK deletion retains the ability to phosphorylate GCV. 8 We developed several TK expression cassettes as shown in Figure 1 . In preliminary studies, we first utilized a strategy involving the use of alternative polyadenylation (poly(A)) sites to restrict TK expression prior to recombination. We generated the SS 2 TP expression cassette to take advantage of the known criteria for poly(A) site selection (for a review see Edwards-Gilbert et al 9 ). In this expression cassette, an intron containing nt 4501-6647 of the BPV genome consisting of parts of the L2 and L1 ORFs was inserted upstream of the TK openreading frame (ORF) and the weak late poly(A) site of polyomavirus. 10 Two poly(A) regions that contain both the early and late poly(A) sites of SV40 were then inserted into the middle of the above BPV sequence such that the upstream BPV a region consisted of 926 bp, while the downstream BPV b region contained 1169 bp ( Figure  1 ). We anticipated that transcripts from this expression cassette would primarily terminate at the strong upstream SV40 poly(A) sites. Western blot analysis using protein extracts from COS-1 cells transfected with SS 2 TP showed that TK expression from this plasmid was nearly as high as in cells transfected with the positive control plasmid S2.1TP that is expected to express high levels of TK (Figure 2) . A faster-migrating band in the Western blot presumably corresponds to a breakdown product of TK. A plasmid containing the GFP gene was used as a negative control and it did not express any TK (Figure 2) . In order to further characterize expression from the SS 2 TP plasmid, a series of Northern blot analyses were performed using total RNA isolated from COS-1 cells transfected with various plasmids. When the Northern blot was probed with the 3S (Figure 3a) . The transcript present in the GFP plasmid presumably corresponds to the GFP transcript, which also contains 5 0 and 3 0 regions that are common to all the plasmids. The blot was then stripped and reprobed with the TK ORF to identify transcripts containing TK sequences (Figure 3b ). The TK probe 5 probe, demonstrating that this transcript corresponds to the TK mRNA (Figure 3b ). No specific band was detectable when the same blot was reprobed with BPV sequences (data not shown). Taken together, the results of Northern blot analyses indicated that only one transcript was produced by the S2.1TP and SS 2 TP expression cassettes, which contains the TK ORF but no BPV sequences. Furthermore, the approximate size of this transcript is consistent with termination of transcription at the polyomavirus poly(A) site, and little or no termination at the SV40 poly(A) sites.
We hypothesized that TK expression by the SS 2 TP plasmid may be due to the fact that the SV40 poly(A) sites closely follow a 5 0 splice site (5 0 ss I) in this plasmid, and the unspliced transcript may not be efficiently terminated/polyadenylated. To eliminate this possibility, we inserted a 3 0 splice site (3 0 ss II) upstream of the SV40 poly(A) sites. We also replaced the SV40 poly(A) dimmer with an SV40 poly(A) trimer to possibly increase the relative strength of the polyadenylation signal. This trimer contains three head to tail copies of a 237 bp segment of SV40 containing both the early and late poly(A) signals. 11 The resulting construct (3S 3 - Figure 1 ) showed greatly reduced TK expression as assayed by Western blot analysis ( Figure 2 ). However, TK expression was not completely eliminated in the presence of this plasmid ( Figure 2 and data not shown). Northern blot analysis of these transfectants indicated that two transcripts of approximately 1400 and 400 nt were produced by this expression cassette (Figure 3a) . The larger transcript hybridized to the TK ORF but not to the BPV sequences ( Figure 3b and data not shown). The smaller transcript contained neither TK nor BPV sequences, consistent with it being an RNA species resulting from the usage of the SV40 poly(A) sites that will contain only 5 0 and 3 0 untranslated regions ( Figure  2b and data not shown). Together, these results suggest that the upstream SV40 poly(A) site is used predominantly in this construct, but the downstream polyoma poly(A) site is also used to a limited extent resulting in low-level TK expression.
It is likely that low-level TK expression from the 3S 3 plasmid is due to alternative splicing from the 5 0 ss I to the 3 0 ss I ( Figure 1 ) by a mechanism similar to exon skipping. As the skipped exon in this system had no 5 Figure 3b and data not shown), demonstrating that the upstream SV40 poly(A) sites were exclusively used in this construct.
Assessment of the ability of homologous recombination to regulate TK expression
The 3S 3 5 plasmid was designed to express TK when this construct is introduced into PV-infected cells but not in uninfected cells. The regulation of TK in this system is expected to depend on homologous recombination between segments of the endogenous PV genomes and PV L1/L2 sequences present in the 3S 3 5 construct. To assess this possibility, we modified 3S 3 5 to create the plasmid 3S 3 5-dF. First, a sequence encoding the FLAG epitope was added upstream of the TK ORF to generate a FLAG-TK fusion to increase the sensitivity of the Western blots. Second, the overall size of the expression cassette was reduced so that it can be incorporated into an AAV vector for studies described later. This was carried out by reducing the size of the BPV a region from 926 to 548 bp. The deletion reduces the total length of BPV sequences (BPV a +BPV b ) from 2098 to 1720 bp. Rubnitz and Subramani 12 have shown that the length of homology between repeated sequences in a transfected plasmid is proportional to the recombination frequency between these sequences, so long as both sequences are over 200 bp in length. The above deletion is expected to cause a small decrease in the recombination frequency between the endogenous PV genome and 3S 3 5-dF as compared to the full-size 3S 3 5 construct. Figure 4 shows that the smaller 3S The use of AAV to deliver an TK expression cassette to PV-infected cells For a therapeutic expression cassette to be useful in vivo, an effective vector must be used for delivery. We, therefore, tested whether AAV, which is capable of infecting mucosal cells (such as those harboring PVs) can be used for the conditional expression of the TK gene. We created a modified version of the 3S 3 Figure 4 Recombination-dependent expression of FLAG-TK in cells transfected with various constructs. Protein lysates made from COS-1 cells transfected with the indicated plasmids were subjected to Western blot analysis using anti-FLAG M2 monoclonal antibodies. S2.1TP-F is a positive control expressing a FLAG-TK fusion. The 3S 3 5-dF cassette was cotransfected into COS-1 cells along with either the negative control plasmid pUC19, the circular BPV plasmid, or a linearized BPV-1 plasmid (BPV-lin). The FLAG-TK fusion protein is indicated by an arrow. A GFP plasmid was transfected into COS-1 cells as a negative control.
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A Carson et al expression cassette, 3S5, in which two of the SV40 poly(A) sites were deleted from the SV40 poly(A) trimer to further reduce the size of the cassette. Our studies had suggested that splice site placement, rather than the relative strength of the poly(A) site, largely determines the polyadenylation pattern in these expression cassettes (data not shown). Therefore, we postulated that there would be little or no effect of reducing the SV40 trimer to a monomer on TK expression. The 3S5 plasmid was found not to express TK as determined by Western blot analysis when introduced into PV-negative COS-1 cells by transfection (data not shown). We then incorporated the 3S5 cassette into the AAV vector, generating AAV-3S5 (Figure 5a ). The AAV-3S5 vector was used to infect BPV-137 cells, a C127 mouse fibroblast cell line that harbors about 1000 BPV-1 genomes per cell, 13 or the parental C127 cells at a multiplicity of infection of 10 000 vector genomes per cell. As the vast majority of viral particles are not infectious in mouse cells (unpublished data), this corresponds to a transducing units of approximately 10 per cell. Since human cell lines containing stably replicating BPV-1 DNA are not available, we utilized the murine BPV-137 cell line in these experiments. This cell line was chosen because it harbors a BPV-1 mutant at a high copy number, which might increase the frequency of recombination over a cell line containing wild-type BPV-1. Since murine cell lines are poorly permissive for AAV infection, cells were pretreated with hydroxyurea to increase the transduction efficiency.
14 Hydroxyurea treatment at these low levels is thought to alter intracellular trafficking and enhance conversion of single-stranded AAV DNA to double-stranded genomes.
14 Also, cell cycle arrest is not seen at these low levels of HU (data not shown). Following infection, TK expression was assayed by Western blot analysis. To reduce the background signals, cell lysates were first immunoprecipitated with an anti-Flag M2-agarose affinity gel, and then subjected to Western blot analysis using anti-TK polyclonal antibodies. As shown in Figure  5b , BPV-137 cells infected with AAV-3S5 expressed TK, while the parental BPV-negative cell line C-127 did not.
This result is similar to that obtained in the cotransfection assay using TK cassettes along with a BPV-1 plasmid (Figure 4 ). These results demonstrate that TK expression can be induced by DNA recombination in BPV-positive cells upon delivery of a nonexpressing cassette by an AAV vector.
The use of rAAV and ganciclovir to eliminate PV-infected cells Although TK expression was detectable through the use of immunoprecipitation followed by Western blot analysis, we wished to determine whether TK levels were sufficient to eliminate PV-infected cells upon treatment with GCV. For this, BPV-137 cells were either mock infected or infected with AAV-3S5. The cells were then treated with GCV for a period of 4 days. Cells were harvested using trypsin and attached cells were counted. As shown in Figure 6 , both infected and uninfected BPV-137 cells rapidly proliferated without GCV treatment. BPV-137 cells that were uninfected but treated with GCV also proliferated rapidly and to nearly the same levels. On the other hand, GCV treatment resulted in over 95% cell death of AAV-3S5-infected cells ( Figure 6 ). Moreover, less than 65% of the remaining AAV-3S5/GCV-treated cells were viable as compared to over 95% viability of untreated control cells as assayed by trypan blue staining (data not shown). These results demonstrate that TK is expressed to levels high enough to sensitize PV harboring cells to killing by GCV treatment.
Discussion
We have developed a DNA recombination-based approach to eliminate PV infection. The efficacy of this approach is dependent on the ability of recombination to promote the expression of a suicide TK gene specifically in cells containing PV sequences. Using a variety of TK constructs, we demonstrate that TK expression can be specifically induced in PV-positive cells presumably as a result of homologous recombination between the cloned PV sequences with those present in the transfected/ infected cells. This approach is expected to result in TK expression only in those cells in which a double crossover recombination event has occurred, resulting in reconstitution of the expression cassette. Single recombination events will not generate a functional transcription The expression of many natural genes is known to be regulated by alternative poly(A) site selection and depends upon both the position and relative strength of the poly(A) sites (reviewed in Edwards-Gilbert et al 9 ). Among identical poly(A) signals, the 5 0 site is favored over a more distal downstream site. 15 Also, when a strong poly(A) site precedes a weak one by a short distance, less than 5% of the processed mRNAs terminate at the weak site. 10 It was somewhat surprising, therefore, that TK expression in SS 2 TP was comparable to S2.1TP with the inclusion of strong upstream polyadenylation sites (Figure 2 . The low levels of expression seen in 3S 3 ( Figure 2 ) may be due to splicing between 5 0 ss I and 3 0 ss I in a mechanism similar to exon skipping. Exon skipping has been shown to decrease when the 5 0 splice site following the skipped exon is strengthened, but increases when the 5 0 splice site is weakened or eliminated.
17 3S 3 contains no 5 0 splice site following the SV40 poly(A) signals, so one was introduced to create 3S 3 5, which does not express TK (Figure 2) .
We have utilized alternative poly(A) site selection as a means to regulate the expression of a suicide gene, TK, in cell lines. TK expression cassettes were developed in which strong SV40 poly(A) site(s) are surrounded by BPV-1 sequences (Figure 1) . Furthermore, the BPV-1 sequences are surrounded by 5 0 and 3 0 splice sites, respectively. Transcription initiated from the upstream SV40 early promoter is expected to generate a primary transcript, which will be spliced utilizing 5 0 ss 1 and 3 0 ss II, resulting in the termination of transcription and polyadenylation at the SV40 poly(A) site. Since the HSV-1 TK gene is located downstream of this region (Figure 1) , little or no expression of the TK gene is expected. This was indeed the case when the COS-1 cell line was transfected with the 3S 3 5 vector (Figures 2 and  3) . These results suggest that proper placement of the poly(A) sites as well as 5 0 and 3 0 splice sites in 3S 3 5 promotes efficient transcription termination, and therefore no detectable TK expression. We included two or three copies of the SV40 poly(A) sequence in some constructs since multiple copies of this sequence were previously found to block spurious transcription in a plasmid containing a promoter-less reporter gene. 11 We tested whether homologous recombination can be used as a means to promote TK expression exclusively in PV-positive cells. For this, we cloned a 2.1-kb region of the BPV-1 L1 and L2 ORFs (nt positions 4501-6647) into the various constructs. Furthermore, the SV40 poly(A) sequence was inserted in the middle of the above region such that the upstream BPV a region consisted of 926 bp, while the downstream BPV b region contained 1169 bp (Figure 1) . The above region of the BPV-1 genome contains no known promoter element, and contains only part of the L1 and L2 ORFs and so it is not expected to express any protein. We hypothesized that when the above constructs are present in BPV-positive cells, homologous recombination between the L1/L2 regions present in the constructs and the BPV-1 genome in cells would result in deletion of the SV40 poly(A) sequence and regeneration of a TK expression cassette in which the polyomavirus poly(A) site present downstream of the TK gene is used for the termination of transcription ( Figure  1 ). Western blot analysis of COS-1 cells cotransfected with the 3S 3 5 and a BPV-1-containing plasmid showed expression of TK (Figure 4 ). Since no TK was expressed in the absence of the BPV-1 plasmid (Figure 4) , these results suggest that the most likely mechanism for the induction of TK expression involves homologous recombination between the L1/L2 regions of the two plasmids. This possibility is further supported by the slight increase in TK expression when the recombination target BPV-1 plasmid was linearized prior to transfection (Figure 4) . Homologous recombination is known to increase when one of the recombination substrates has linear ends. 5 For a therapeutic expression cassette to be useful in vivo, an effective vector must be used for delivery. AAV is an ideal viral vector for this application since it commonly infects humans, but is not known to cause any human disease. 18 It has the ability to infect efficiently many types of dividing and nondividing cells. 18 Wildtype AAV-2 has also been found in significant numbers of cervical epithelial cells from patients, indicating that AAV can infect cells harboring mucosa-tropic HPVs. 19 Our experiments using the AAV-3S5 construct showed that TK is expressed in BPV-positive cells but not in BPVnegative cells (Figure 5b ). These results suggest that homologous recombination between the L1/L2 sequences in the TK cassette and the BPV-1 genome results in the expression of the TK gene specifically in BPV-1-positive cells.
The results of our studies demonstrate that homologous recombination can be used as a means to express a suicide gene, TK, in virally infected cells. Such cells are then sensitive to treatment with the well-established antiherpesvirus drug GCV allowing elimination of over 95% of PV-infected cells ( Figure 6 ). This will allow us to develop a strategy in the future to eliminate specifically HPV-infected cells using GCV. Also, due to the wellknown 'bystander effect' of TK, HPV-positive cells within a lesion that are not infected by the TK cassette are also likely to be eliminated by GCV treatment. An approach to eliminate PV-infected cells has been described by Sethi and Palefsky, 20 whereby TK expression is transcriptionally regulated by the presence of the viral E2 protein. We have developed an entirely different approach in which only the presence of viral DNA is required for TK expression.
Many high-risk HPVs such as types 16 and 18 are associated with the development of cancer of the cervix and oral cavity. [1] [2] [3] [4] Frequently, the HPV DNA is integrated into the genome in cancers which express the viral E6 and E7 oncogenes to high levels. [1] [2] [3] [4] The mechanisms and/or events that promote integration of the HPV genome are not well known. Therefore, any approach for the elimination of high-risk HPVs from infected cells will have to be carefully developed so as not to promote integration of the viral DNA into the genome. However, low-risk HPVs such as types 6 and 11 cause long-term infections and painful lesions but are rarely associated with the development of cancers. [1] [2] [3] [4] Their inability to promote malignant transformation is primarily due to Recombination-based elimination of papillomavirus A Carson et al the fact that their E6 and E7 oncoproteins do not inactivate the functions of the cellular tumor suppressor proteins such as p53 and pRB. [1] [2] [3] [4] Thus, the strategy described in this report can be readily adapted for the treatment of lesions caused by low-risk HPVs. Also, since TK expression is limited to infected cells, this approach is likely to have little effect on uninfected cells. Finally, our recombination approach may also be potentially useful for the elimination of other viral infections.
Materials and methods
Oligonucleotides
The following primers were used for the amplification of DNA for cloning: 
DNA constructs
A truncated version of the TK ORF 8 was PCR amplified using primers TK-forward and TK-reverse. The ORF was then isolated as a BglII/MluI fragment. The weak PV poly(A) site was PCR amplified from the wild-type A2 strain of PV using primers polyoma-forward and polyoma-reverse. This poly(A) site was then isolated as a MluI/XbaI fragment. These two fragments were then ligated into BglII/XbaI-digested plasmid pSG5 (Stratagene) in a three-way ligation to create pSTP. The BPV-1 genome from nt 4501 to base 6647 containing portions of the L1 and L2 ORFs was PCR amplified using primers BPV-forward and BPV-reverse. This region was then isolated as an EcoRI fragment and cloned into the MfeI site of pSTP to create plasmid S2.1TP. The SV40 poly(A) site of pSG5 was isolated as a 160-bp BamHI/XbaI fragment, the ends were filled-in with Klenow fragment of DNA polymerase I and ligated into the filled-in NheI/ ClaI site within the 2.1-kb BPV sequence described above. The NheI/ClaI digestion within the BPV-1 sequence resulted in the loss of 46 bp from the BPV sequence between the BPV a and BPV b regions. An EcoRI fragment containing two SV40 poly(A) sites in the forward orientation along with the adjacent BPV a and BPV b sequences was then isolated and cloned into the MfeI site of pSTP to create SS 2 TP. The SV40 poly(A) trimer was released from plasmid pUCA15 10 via HpaII/ BglII digestion. A double-stranded oligonucleotide with BglII and NheI ends containing the 3 0 ss II sequence along with the above SV40 poly(A) trimer was ligated into the NheI/ClaI site of the 2.1-kb BPV fragment described above in a three-fragment reaction. These elements were then isolated as an EcoRI fragment and cloned into the 5 -dF. The same FLAG epitope was also inserted into the EcoRI site of S2.1TP to create S2.1TP-F. We also generated the AAV-3S5 vector for delivery of the TK cassette into murine cells. This involved cloning of a TK cassette similar to 3S 3 5-dF, except containing a single SV40 poly(A) site in place of a trimer, into the AAV vector pXX. For this, two regions of 3S 3 5-dF cassette were amplified, one containing the SV40 promoter and the BPV a region (using primers 3S5A-forward and 3S5A-reverse) and the second containing one copy of the SV40 poly(A) signal, BPV b region, the TK ORF and the polyomavirus poly(A) signal (using the primers 3S5B-forward and 3S5B-reverse). The first region was then isolated as a BclI/BglII fragment and the second as a BclI fragment. These two fragments were then simultaneously ligated into the BglII sites of plasmid pXX containing the AAV inverted terminal repeats to generate the AAV-TK plasmid pXX-3S5.
Virus production
The AAV used was serotype 2. The recombinant viral stocks were produced according to the adenovirus-free, three plasmid cotransfection method. 21 Briefly, the AAV-TK vector plasmid pXX-3S5 was cotransfected into human 293 cells with the helper plasmids pXX2 21 (supplying rep-cap function) and pXX6 22 (a truncated adenovirus plasmid supplying E2a, E4, and VA RNA). Cells were harvested 48 h after transfection, and then frozen and thawed four times. The viral particles were purified from the crude lysate using an FPLC-Heparin column. 21 Virus particle numbers were determined by quantitative DNA dot-blot analysis. 22 Recombination-based elimination of papillomavirus A Carson et al Transfections COS-1 cells were transfected with the lipofectamine reagent (Gibco). Transfections were performed according to the supplier's instructions in 60 mm dishes seeded with 2-3 Â 10 6 cells, 3 mg total DNA, and 30 ml lipofectamine reagent per transfection.
Infections
BPV-137 or C-127 cells were plated 1 day prior to infection at a density of 2-3 Â 10 5 cells per 60 mm dish. The next morning, cells were treated with 3 mM hydroxyurea for 2-3 h in complete DMEM media. Following this treatment, cells were washed and complete media containing 5 Â 10 9 viral particles was added. Infections were allowed to proceed overnight, the cells were again washed, and complete media were added.
Western blots
Western blots were performed as described. 22 Primary rabbit polyclonal anti-TK antibodies were purchased from William Summers at Yale University and used at a 1:400 dilution. Primary anti-FLAG M2 monoclonal antibodies were purchased from Sigma and used at a 1:1000 dilution.
RNA isolation and Northern blots
RNA was isolated using the ULTRASPEC RNA Isolation Kit from Biotecx according to the manufacturer's instructions. Northern blot analysis was performed by standard methods. 22 The radiolabeled probes were prepared by random primer labeling of restriction enzyme fragments or whole plasmids. 22 The blots were stripped by boiling in 25 mM phosphate buffer (pH 7.2) with 5 mM EDTA and 1% SDS.
GCV treatment
BPV-137 cells were plated 1 day prior to infection at a density of 2-3 Â 10 5 cells per 60 mm dish (in triplicate). The next morning, cells were treated with 3 mM hydroxyurea for 2-3 h in complete DMEM media. Following this treatment, cells were washed and complete DMEM medium containing 5 Â 10 9 viral particles was added. Infections were allowed to proceed overnight, the cells were again washed, and complete DMEM medium was added. 23 GCV was added to a concentration of 50 mM and selection was allowed to proceed for 4 days. 24 
